Imperative Care secures USD100M to advance robotic stroke treatment platform

USA—Imperative Care, a developer of stroke treatment hardware, has secured USD100 million in convertible note financing to support its commercial growth and advance research into its upcoming robotic platform.

The former Fierce Medtech Fierce 15 winner attracted investments from new backers Elevage Medical Technologies and Perceptive Advisors, who co-led the funding round.

New and returning investors participated in the financing, including Catalio Capital Management, Longaeva Partners, Brown Advisory, Ally Bridge Group, and Bain Capital Life Sciences.

As part of the agreement, Elevage CEO Evan Melrose will join Imperative Care’s board of directors. Patient Square Capital launched Elevage in 2023.

Innovative catheter technology for clot removal

Earlier this year, Imperative Care introduced the latest catheter in its Zoom aspiration system, which removes blood clots from the brain.

The Zoom 4S features an asymmetric tip similar to its predecessor models, providing enhanced engagement and improved suction at the catheter-clot interface while smoothly navigating through twisting blood vessels.

The device works in conjunction with the company’s large-bore intracranial access and continuous suction systems.

These technologies deliver direct aspiration on the first pass, enabling physicians to quickly address life-threatening blockages.

The design prioritizes speed and efficiency, critical factors in stroke treatment where every minute counts.

Expanding product portfolio

Last September, the FDA cleared Imperative Care’s Symphony large-bore vacuum system for the treatment of pulmonary embolism.

This approval expanded the company’s reach beyond stroke treatment into broader vascular applications.

Imperative Care reports that medical professionals have used its products commercially in more than 78,000 procedures, demonstrating significant market adoption and clinical trust.

Developing robotic endovascular solutions

Imperative Care’s Telos Health unit has been developing a robotic endovascular system to guide and manipulate catheters during ischemic stroke treatment.

The system will enable physicians to perform procedures both on-site and remotely through telesurgery capabilities.

This advancement could transform stroke care delivery by allowing specialists to treat patients in remote locations where expert intervention may not be immediately available.

The robotic platform represents a significant technological leap in endovascular intervention, potentially expanding access to specialized stroke care across underserved regions.

The technology aims to maintain precision and control while offering flexibility in how and where treatments occur.

Leadership vision for growth

Fred Khosravi, CEO of Imperative Care, highlighted the significance of the funding.

“This financing reflects the strong momentum we have built and the confidence our investors—new and existing—have in our vision,” he said.

Khosravi emphasized that the company expands access to life-saving technologies for patients during the most critical moments of their lives.

The capital positions Imperative Care to continue driving forward its mission across stroke, vascular applications, and beyond.